Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target and Financial Performance

Core Viewpoint - Mirum Pharmaceuticals is focused on developing therapies for rare liver diseases, with significant revenue growth driven by innovative treatments like Livmarli and bile acid drugs [1][6]. Financial Performance - Mirum reported a 50% increase in revenues for the fourth quarter, driven by strong sales of Livmarli and bile acid drugs, despite incurring a net loss [3][6]. - The company has a market capitalization of approximately $4.77 billion, indicating its size and market presence [5][6]. Stock Performance - Currently, MIRM's stock is priced at $92.22, reflecting a 15.10% decrease, with fluctuations between $90.26 and $100.19 on the trading day [4][6]. - Over the past year, the stock reached a high of $107.41 and a low of $36.88, indicating significant volatility [4]. Analyst Outlook - RBC Capital set a price target of $128 for MIRM, suggesting a potential upside of about 36% from its trading price of $94.14 at the time [2].